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 Abstract
Introduction: According to WHO data, among patients infected with HIV, tuberculosis occurs in about 30% of patients and causes 
approximately 25% of deaths due to AIDS worldwide. The incidence rate of tuberculosis in the Polish population was 22.2/100,000 
in 2011, while the average in European Union countries in 2011 was 14/100,000. Since 1985 to 30 April 2013 HIV infection in 
Poland was confirmed in 16,588 patients, while the number of reported tuberculosis cases in HIV-infected individuals in 2011 
was 26. The aim of this study was to assess the prevalence and clinical course of tuberculosis and mycobacterial disease in 
HIV-infected patients treated in the Department of Infectious Diseases and Hepatology in Białystok.
Material and methods: We analysed documentation of 577 HIV-infected patients, their demographic data, epidemiological status, 
degree of immunosuppression (T CD4 and CD8 numbers) and stage of HIV infection.
Results: Complete follow-up was possible in 389 patients, of whom 265 (68%) were male. Tuberculosis (TB) was diagnosed in 41 
patients (10.5%) and mycobacteriosis in 4 patients (1.03%). In 19 patients (42%) HIV and TB or mycobacteriosis were diagnosed 
simultaneously. The median CD4 T lymphocyte count was lower in patients with a simultaneous diagnosis of HIV and tuberculosis 
or mycobacteriosis compared to the group in whom TB/mycobacteriosis was diagnosed later. The number of CD4 T-cells less 
than 50 cells/μL was found in 63.2% (12/19) of patients when HIV and TB or mycobacteriosis were diagnosed simultaneously 
and in 38.5% (10/26) of patients who were diagnosed with TB or mycobacteriosis later than the HIV infection (p = 0.14). The 
median HIV viral load in patients in whom HIV infection and tuberculosis or mycobacteriosis were diagnosed at the same time was 
higher than in other patients and this difference was statistically significant. Pulmonary tuberculosis was the most common form 
of clinical disease and accounted for 60% of all cases. Among the analysed cases with HIV and tuberculosis or mycobacteriosis 
coinfection, tuberculosis or mycobacteriosis was the cause of death in 8 patients, and 9 died of other causes.
Conclusion: In our material of 389 HIV-infected patients, tuberculosis was diagnosed in 41 (10.5%) and mycobacterial diseases 
in 4 (1.03%). In 42% of co-infected patients (HIV+TB or mycobacteriosis) the diagnosis of both diseases was made at the same 
time. In these patients, a deep deficit of cellular immunity (CD4 < 50 cells/μL) was observed more frequently than in patients 
diagnosed with TB or mycobacteriosis in the later course of HIV. HIV RNA viral load was significantly higher in the group diagnosed 
simultaneously than in the remaining patients with HIV and TB or mycobacteriosis coinfection.
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Streszczenie
Wstęp: Zgodnie z danymi WHO wśród pacjentów zakażonych HIV, gruźlica występuje u około 30% pacjentów i jest przyczyną oko-
ło 25% zgonów z powodu AIDS na świecie. Zapadalność na gruźlicę wśród populacji polskiej w 2011 roku wynosiła 22,2/100 000, 
natomiast średnia zapadalności w krajach Unii Europejskiej w 2011 roku — 14/100 000. W Polsce, od 1985 roku do 30 kwietnia 
2013 roku potwierdzono 16 588 zakażeń HIV, natomiast liczba zgłoszonych w 2011 roku przypadków gruźlicy u zakażonych HIV 
wynosiła 26 przypadków. Celem pracy była ocena częstości i objawów klinicznych gruźlicy i mykobakterioz w materiale chorych 
zakażonych HIV, hospitalizowanych w Klinice Chorób Zakaźnych i Hepatologii Uniwersytetu Medycznego w Białymstoku.
Materiał i metody: Analizowano dokumentację 577 chorych zakażonych HIV. Analizowano dane demograficzne, epidemiologicz-
ne, stan układu immunologicznego w zakresie limfocytów T CD4 i CD8, fazę zakażenia HIV.
Wyniki: Pełna obserwacja możliwa była u 389 pacjentów, z których 265 (68%) to mężczyźni. Gruźlicę rozpoznano u 41 pacjentów 
(10,5%), mykobakteriozy u 4 pacjentów (1,03%). U 19 pacjentów (42%) rozpoznanie gruźlicy lub mykobakteriozy było równoczaso-
we z diagnozą HIV. Mediana liczby limfocytów T CD4 była niższa u pacjentów z równoczesnym rozpoznaniem gruźlicy i zakażenia 
HIV w porównaniu do grupy, u której gruźlicę rozpoznano później. Liczbę limfocytów T CD4 niższą niż 50 kom./μl stwierdzono 
u 63,2% (12/19) pacjentów, u których zakażenie HIV i gruźlicę (albo mykobakteriozę) rozpoznano równocześnie oraz u 38,5% (10/26) 
pacjentów, u których te choroby rozpoznano w późniejszym czasie (p = 0,14). Mediana wiremii HIV u pacjentów, u których zaka-
żenie HIV i gruźlicę lub mykobakteriozę zdiagnozowano równocześnie, była wyższa niż u pozostałych pacjentów i różnica ta była 
istotna statystycznie. Gruźlica płuc była najczęstszą postacią kliniczną choroby i stanowiła 60% wszystkich przypadków. Wśród 
analizowanych przypadków pacjentów z współwystępowaniem gruźlicy lub mykobakteriozy i HIV, gruźlica/mykobakterioza była 
przyczyną zgonu 8 pacjentów, natomiast 9 zmarło z innych przyczyn.
Wnioski: W badanej populacji pacjentów gruźlicę rozpoznano u 41 pacjentów (10,5%), a mykobakteriozę u 4/389 pacjentów 
(1,03%). W 42% przypadków wśród badanych osób rozpoznanie zakażenia HIV i gruźlicy nastąpiło równoczasowo. W tej grupie 
chorych częściej obserwowano głęboki deficyt odporności komórkowej (limfocyty T CD4 < 50 kom./μl), a wiremia HIV RNA była 
istotnie wyższa niż w grupie chorych z HIV, u których gruźlicę lub mykobakteriozę rozpoznano później.
Słowa kluczowe: współwystępowanie, HIV, gruźlica, prątki atypowe, mykobakterioza, epidemiologia
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Introduction
According to the World Health Organization, 
8.7 million cases of tuberculosis (TB) and 1.4 
million deaths due to tuberculosis were registered 
in 2011. Tuberculosis is the second, in respect 
of frequency, cause of death due to infectious 
diseases in the general population, and it is listed 
among the top ten causes of deaths worldwide. 
1/3 of the worldwide population (the general 
population and patients infected with human 
immunodeficiency virus) is infected with tubercle 
bacilli with no symptoms of the disease (the so-
called latent tuberculosis). Whereas, HIV-infected 
patients, due to immunodeficiency (mainly decre-
ased cellular immunity), are about 21–34 times 
more prone to develop active TB in comparison 
with the general population. In 2011, 1.1 million 
new TB cases among HIV-infected patients were 
registered worldwide, which accounts for 13% of 
all TB incidence in the general population. On 
a global scale, since 2004, the mortality rate due 
to TB among HIV-infected patients has decreased 
by approximately 25%, but it still remains the 
cause of one out of four deaths due to acquired 
immunodeficiency syndrome (AIDS). More than 
70% of cases of HIV and TB coinfection occur in 
Africa [1, 2]. 
A total of 8,478 cases of TB were diagnosed in 
the Polish population in 2011, and the incidence 
rate was 22.2/100,000; new cases amounted to 
19.7/100,000 and recurrences to — 2.5/100,000. 
In 2012, 7542 cases of TB were diagnosed, the 
incidence rate decreased to 19.6/100,000, new 
cases amounted to 17.3/10,000 and recurrences 
to 2.3/100,000 [3]. In European countries in 2011, 
71,031 cases of tuberculosis were diagnosed, and 
the mean TB incidence was 14/100,000 [4].
 In Poland, since the introduction of HIV 
diagnostic tests in 1985 until April 30th 2013, 
16,588 cases of HIV infection were diagnosed. 
The number of new cases is not decreasing and 
a growing number of sexually (hetero- and homo-
sexual) transmitted HIV infections is observed 
[5–7]. During this period, there were 2908 cases 
of AIDS registered in Poland and 1207 cases of 
death due to this disease [8]. According to the 
data of the National Institute of Public Health, 
the following number of new cases of HIV/
AIDS were diagnosed: in 2008 — 958/207 in 
2009 — 716/127, in 2010 — 747/173, in 2011 
— 1188/241. 
According to the European Centre for Disease 
Prevention and Control (ECDC), there were 27 
cases of the coincidence of HIV and TB in 2009 
in Poland, 22 — in 2010 and 26 in 2011. 
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In European Union countries (the European 
Economic Area) 1334 cases of HIV infection in 
patients with TB were reported in 2009, 1055 — 
in 2010, and 1003 in 2011 [4]. The last report on 
HIV/TB coincidence by the ECDC did not take into 
account several countries, including Poland, due 
to a lack of data concerning the number of perfor-
med tests checking HIV infection in TB patients. 
According to the ECDC and the WHO, the number 
of HIV-infected people and the number of TB and 
HIV coinfections worldwide is underestimated 
[2, 4]. Even more than 50% of people are not awa-
re of being infected with HIV [9, 10]. According 
to the WHO, only 40% of TB patients worldwide 
underwent testing directed at HIV infection; this 
proportion was even lower in European countries, 
and in 2009 it amounted to 23.9%. However, it 
should be emphasized that since 2004 the number 
of performed tests directed at HIV infection in TB 
patients has increased worldwide more than ten 
times [2]. In Europe in 2011, 53.6% of TB patients 
underwent testing directed at HIV infection [4]. 
In Poland, specialized extensive medical care 
of HIV-infected patients with coexisting TB or my-
cobacteriosis is provided in 17 centres localized 
in 14 cities, in cooperation with the agenda of the 
Ministry of Health — the National AIDS Centre. 
The aim of the present study was a retrospec-
tive, clinical and epidemiological analysis of the 
incidence of TB and mycobacteriosis in patients 
with confirmed retroviral infection, treated at the 
Department of Infectious Diseases and Hepatolo-
gy of the Medical University of Białystok, coming 
from the Podlasie, Warmia and Mazury regions. 
Material and methods
Medical documentation of 577 HIV-infected 
patients from the period from 1989 to 2011 was 
analysed. Diagnosis of HIV was based on sho-
wing the presence of anti-HIV antibodies in two 
screening enzyme-linked immunosorbent assays 
(ELISA), confirmed by western blot method. Tu-
berculosis and mycobacteriosis were diagnosed 
based on clinical symptoms, microbiological 
examinations, results of direct smears, cultures on 
solid and fluid media, histological and radiological 
examinations (X-rays, MRI — magnetic resonance 
imaging, CT — computed tomography, ultrasono-
graphy). The following factors were analysed: age 
of patients, sex, route of HIV transmission, T CD4 
lymphocytes count and HIV viral load at the time 
of diagnosis of HIV and TB or mycobacteriosis, the 
date of diagnosis of HIV and TB/mycobacteriosis 
infection, and the time that passed between dia-
gnosis of the two diseases. In statistical analysis 
the Mann-Whitney U test, Fisher’s exact test and 
t-Student test were used. The Statistica program 
was used to conduct statistical tests.
Results
From the group of 577 HIV-infected patients, 
data concerning infective complications were 
registered in 389 patients. 265 (68%) out of them 
were males from 18 to 67 years of age, and 124 
(32%) were females from 18 to 64 years of age. The 
remaining 188 patients, who were seen during 
single visits, were not included in the analysis. 75 
deaths (13%) were registered in the whole group 
(n = 577) during the study period. 
Patients who probably had been infected 
with HIV through intravenous drug use (IVDU) 
accounted for 55% (214/389), through heterosexu-
al relations — 12.5% (49/389) and homosexual 
relations — 10% (39/389), in 22.5% of patients 
(87/389) the route of transmission was not esta-
blished (Table 1). 
Tuberculosis was diagnosed in 41 out of 389 
patients (10.5%), and mycobacteriosis in 4 pa-
tients (1.03%). The mycobacteria species inden-
tification revealed in 1 patient — Mycobacterium 
avium complex (MAC) aetiology, in 2 patients 
— Mycobacterium kansasii, and in 1 patient the 
species was not identified. 
Males predominated among patients coinfec-
ted with HIV and TB — 34/41 (75.6%) (Table 1). 
Table 1.Characteristics of the study population
Tabela 1. Charakterystyka badanej populacji
Number of analysed patients — n (%) 389 (100%)
Sex n (%) Female 124 (32%)
Male 265 (68%)
Route of HIV transmission n (%) Homosexual 39 (10%)
Heterosexual 49 (12.5%)
IVDU* 214 (55%)
Uknown 87 (22.5%)
Patients co-infected  
with HIV and tuberculosis — n (%)
41 (10.5%)
Sex n (%) Female 7 (15.6%)
Male 34 (75.6%)
Patients co-infected  
with HIV and mycobacteriosis — n (%)
4 (1.03%)
Sex n Female 1
Male 3 
*intra venous drug use
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16/41 (39%) patients were diagnosed simulta-
neously with TB and HIV/AIDS. Among patients 
with mycobacteriosis, the two diseases were dia-
gnosed simultaneously in 3/4 patients (Table 2). 
In the remaining patients, TB or mycobacteriosis 
were diagnosed on average 5.7 years after the 
diagnosis of HIV. At the moment of diagnosis of 
TB or mycobacteriosis, 16 (36.6%) patients were 
actively drug or/and alcohol dependent. 
The median T CD4 lymphocyte count in the 
group with diagnosed TB was 53 cells/μL, whereas 
in the group with diagnosed mycobacteriosis it was 
45 cells/μL (p = 0.57). The median T CD4 lymphocyte 
count was lower in patients with simultaneous dia-
gnosis of HIV and TB/mycobacteriosis (44.5 cells/μL) 
compared to those in whom TB or mycobacteriosis 
was diagnosed later (68.0 cells/μL), but the difference 
was not statistically significant (p = 0.26) (Table 2). 
T CD4 lymphocyte count was found to be lower than 
200 cells/μL in 73.7% (14/19) of patients in whom 
coinfection with HIV and TB/mycobacteriosis were 
diagnosed simultaneously, and in 80.8% (21/26) of 
patients, who had previously diagnosed HIV and TB 
or mycobacteriosis was diagnosed later (p = 0.72) 
(Fig. 1). With the cut off point at the level of 50 cel-
ls/μL, these proportions amounted to 63.2% (12/19) 
and 38.5% (10/26) (p = 0.14), respectively (Table 3). 
The mean HIV viral load during diagnosis of TB 
was 4.88 log 10 copies/mL, and during diagnosis 
of mycobacteriosis it was  5.08 log 10 copies/mL 
(p = 0.64). The mean HIV viral load in patients who 
had HIV infection and TB diagnosed simultaneously 
amounted to 5.23 log 10 copies/mL (n = 9), whereas 
in the remaining patients it was 4.18 log 10 copies/mL 
(n = 15); the difference was statistically significant 
(p = 0.04) (Table 2). 
Positive results of direct smears were obtained 
in 15 (33%) patients: the presence of acid-fast ba-
cilli in sputum was found in 12 patients, in urine 
— in 2 patients, and in direct smears of lymph 
node biopsy specimen — in 1 patient. Acid-fast 
bacilli were cultured from clinical material in 30 
(67%) patients, from sputum — in 26 patients, 
from urine — in 2 patients, and from cerebrospi-
nal fluid and pleural fluid —  in one patient each. 
Tuberculosis was diagnosed with the help of hi-
stopathological examination of peripheral lymph 
nodes in 6 patients (in 2 patients at autopsy), and 
in one patient — based on the result of a positive 
genetic study (Table 4). The most frequent clinical 
Table 2. Characteristics of patients co-infected with HIV and tuberculosis or mycobacteriosis
Tabela 2. Charakterystyka pacjentów z współwystępowaniem HIV i gruźlicy lub mykobakteriozy
Age at diagnosis HIV (years) 28 (17–51)
Route of HIV transmission n (%) Homosexual 4 (8.9%)
Heterosexual 5 (11.1%)
IVDU# 27 (60%)
Uknown 9 (20%)
Age at diagnosis Tbc or mycobacteriosis (years) 31.5 (19-52)
Simultaneous with HIV 31 (24-49) p = 0.89
Later than HIV 32 (19-52)
Diagnosis 
TB n (%)
Simultaneous with HIV 16  (39%)
Later than HIV 25  (61%)
Diagnosis
of mycobacteriosis n
Simultaneous with HIV 3
Later than HIV 1
Lymphocytes T CD4 (cells/μL)€ Mycobacteriosis + HIV 45 (19–203) p = 0.57
Tuberculosis + HIV 53 (3–993)
Lymphocytes T CD4 (cells/μL)€
TB/Mycobacteriosis
Simultaneous with HIV 44.5 (3–993) p = 0.26
Later than HIV 68 (4–391)
HIV viral load (log 10 copies/mL)* Mycobacteriosis + HIV 5,08 (SD = 1,22) p = 0.64
Tuberculosis + HIV 4,88 (SD = 0,56)
HIV viral load (log 10 copies/mL)*
TB/Mycobacteriosis
Simultaneous with HIV 5.23 (SD = 0,56) p = 0.04
Later than HIV 4.18 (SD = 1,41)
#intra venous drug use; €median (range); *mean (standard deviation SD)
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Table 3. Number of CD 4 T — cells at diagnosis of tuberculosis or mycobacteriosis
Tabela 3. Liczba limfocytów T CD 4 w chwili rozpoznania gruźlicy lub mykobakteriozy
Lymphocytes
T CD4+ (cells/μL)
Cases of mycobacteriosis Cases of tuberculosis
Simultaneous 
with HIV diagnosis
n = 3
After prior HIV  
diagnosis
n = 1
Simultaneous with 
HIV diagnosis
n (%) = 16 (40)
After prior HIV  
diagnosis
n (%) = 25 (56)
p
< 50 1 1 11 (69)
12 (75)
9 (36)
20 (8)
0.14
0.72
50–200 1 – 1 11(4)
200–500 1 – 2 5 (20)
> 500 – – 2 0
Figure 1. Number of observed cases of TB depending on the number of T CD4 lymphocytes during diagnosis
Rycina 1. Liczba obserwowanych przypadków Tbc w zależności od liczby limfocytów T CD4 podczas rozpoznania
Table 4.Performed tests in the diagnosis of tuberculosis or mycobacteriosis
Tabela 4. Badania wykonane w procesie diagnostycznym gruźlicy lub mykobakteriozy
Type of test performed Result
Positive, n Negative, n
Direct smears 15 30
Clinical specimens culture media
(tubercle bacilli): (atypical mycobacterial bacilli)
(26) : (4) 15
Histopathology 6
PCR 1 –
Radiology 
examination
Chest X-ray 33 4
USG 3 –
MRI 4 –
CT 9 –
PCR — polymerase chain reaction; RTG — chest X-ray; CT — computed tomography; MRI — magnetic resonance imaging; USG — ultrasonography
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form of TB was pulmonary disease, which was 
diagnosed in 27 patients (60%). Among 18 pa-
tients with extrapleural forms, disseminated TB 
was diagnosed in 15 patients (36.6%), lymphatic 
TB — in 2 (4.9%) patients, and pleural TB — in 
1 patient. Four cases of disseminated TB were con-
firmed during postmortem pathomorphological 
examination of various tissues. Mantoux test was 
performed in 9 patients, and a positive reaction 
(> 6 mm) was obtained in 3 cases. 
Mycobacteriosis was diagnosed in 4 pa-
tients based on symptoms of the disease, X-ray 
examination and confirmed presence of atypical 
mycobacteria in biological material. In one case 
it was the species Mycobacterium kansasii, in 
two cases it was MAC, and in one patient the 
species was not established and the strain was 
recognized as mycobacteria other than tuber-
culosis (MOTT). In this group of patients two 
persons had the pleural form of the disease, and 
two had disseminated. 
About three weeks after the beginning of 
antiretroviral treatment, TB symptoms appeared 
in 2 patients without prior diagnosis of TB, and 
intensification of symptoms in patients with 
already diagnosed TB was observed in 7 patients. 
Based on clinical manifestation and additional 
examinations, in these 9 patients, immune recon-
stitution syndrome was recognized. Among the 
analysed patients with HIV and TB or mycobac-
teriosis coinfection, the direct cause of death in 
6 patients was TB, mycobacteriosis — in 2, and 
9 patients died of other reasons. 
Discussion
As one of the diseases which most frequently 
accompany HIV infection, TB is used as an AIDS 
indicator [11]. It is considered that 1/3 of the ge-
neral population worldwide is infected with TB, 
and intravital risk of active TB is 5–10% [11–13]. 
European epidemiologic studies show an incre-
ased risk of TB in HIV-infected male patients, 
drug-addicts, alcoholics, patients with low T CD4 
lymphocytes count, high HIV viral load, and of 
Eastern European origin, which is in accordance 
with the results of the present study [13].
In Poland the death rate due to TB amounted 
to 1.7/100,000 in 2011, and it is approximately 
twice as high as the death rate in older countries 
of the European Union; however, since 1995 it has 
shown a downward tendency [2–4]. In Poland in 
2010 the proportion of deaths due to TB was 0.2% 
of all deaths due to other reasons, and 26.7% of all 
deaths due to infectious diseases. Mortality due 
to TB in the Polish population in 2009 was 743 
(9.02%) deaths of all 8236 TB cases, in 2010 it 
was 575 (7.66%) of 7,509, and in 2011 it was 640 
(7.55%) of 8478 [14]. In the present study, of the 
75 deaths in the observed population, 6 (8%) were 
caused by TB and 2 (2.7%) by mycobacteriosis. 
In the group of patients with HIV and TB, morta-
lity due to TB was 14.6% (6/41). Two out of four 
patients with diagnosed mycobacteriosis died. 
One of the reasons for the high mortality due 
to TB or mycobacteriosis in the study group was 
the fact that in many patients HIV infection was 
recognised at late stage, simultaneously with TB 
or mycobacteriosis. At the late stage of HIV infec-
tion, a deep suppression of the immune system 
and high values of HIV viral load are observed, 
which is combined with a poor prognosis. In 
patients, who had HIV infection diagnosed at the 
late stage of the disease (late presenters), recon-
struction of the immune system during antire-
troviral treatment is slow, despite the increasing 
absolute number of lymphocytes, their function is 
disturbed, and prognosis as to long survival is bad. 
According to the reports, antiretroviral treatment 
of HIV-infected patients significantly decreases 
mortality due to TB in the case of coincidence of 
the two diseases. In some cases, despite the ap-
plied antiretroviral treatment, the patient’s poor 
compliance with the treatment is directly respon-
sible for ineffective therapy, and indirectly — for 
high mortality in this group [15]. Furthermore, 
in the analysed group of patients with TB or my-
cobacteriosis, 16 (36.6%) patients were actively 
drug or/and alcohol dependent, which made the 
treatment considerably more difficult, and to some 
extent, was the cause of therapy failure.
According to the WHO, multi-drug resistant 
TB strains (MDR-TB) are the cause of active TB in 
approximately 3.7% of new TB cases and in about 
20% of previously treated cases. It is estimated 
that approximately 60% of all MDR-TB cases are 
registered in India, China and the Russian Federa-
tion. Due to its close location to Poland, it is wor-
rying that the proportion of MDR-TB in Belarus 
amounts to 32.3%. Extensively, drug resistant TB 
(XDR-TB) was already identified in over 84 coun-
tries worldwide, and it is estimated that among 
MDR-TB strains, its proportion reaches approxi-
mately 9% [2, 12, 16]. According to epidemiolo-
gical data, the prevalence of MDR-TB in Poland is 
low. 32 cases of TB caused by MDR-TB, including 
1 case of XDR-TB were found in 2010. 109 cases 
of drug-resistant TB caused by strains resistant 
to at least 1 tuberculostatic drug, and 36 MDR-TB 
cases, were registered in 2011. It accounted, re-
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spectively, for 1.3% and 0.4% of all reported TB 
cases in 2011 [3, 17, 18]. We did not find MDR-TB 
cases in the present study but, according to the 
literature, the number of registered cases incre-
ases together with longstanding observation [19]. 
In Poland drug-sensitivity is examined in all pa-
tients in whom tuberculous bacilli are cultured. 
The methodology of the examination and pro-
blems connected with the culture of bacillus, i.e. 
a very long cell cycle (cell division every 24 h) 
often complicates and delays the introduction 
of the proper treatment. Moreover, the clinical 
course of TB or mycobacteriosis in patients with 
a deep immunodeficiency often has an atypical 
character. The above-mentioned difficulties may 
result in delayed treatment and inappropriate 
choice of tuberculostatic drugs, which may lead to 
ineffective therapy and development of acquired 
drug-resistance [20].
Due to a lack of obligation to report mycobac-
teriosis cases to the register, data concerning the 
prevalence of the disease in Poland are underesti-
mated. According to American statistical data, the 
incidence of mycobacteriosis worldwide ranges 
from 1 to 1.8 per 100,000 persons [21]. Patients 
with acquired or congenital immunodeficiency 
syndromes, and, among them, the population of 
HIV-infected patients, are the high risk group for 
mycobacteriosis and for death due to the disease 
[22, 23]. In the present study, two out of four cases 
of diagnosed mycobacteriosis ended with death. 
In one case mycobacteriosis of Mycobacterium 
kansasii aetiology was diagnosed in a Vietnamese 
citizen, in whom HIV infection was diagnosed 
at the same time (the so-called late presenter). 
Laboratory investigations showed a deep deficit 
in immunity — the number of T CD4 lympho-
cytes was 19 cells/μL. Mycobacteriosis in this 
patient is typical of HIV-infected patients with 
a considerable deficit in immunity. At the level 
of T CD4<50 cells/μL mycobacteriosis should 
be taken into account in differential diagnosis of 
opportunistic infections. 
The second case concerned a Polish citizen, 
who also had HIV infection diagnosed at the 
advanced stage of immunodeficiency syndrome 
(indicator of the disease — septicaemia of Sal-
monella spp. aetiology). Then, antiretroviral tre-
atment was introduced immediately. The patient 
was hospitalized again about half a year later, 
with consciousness disturbances, periodically 
with psychotic symptoms, fever, cachexy, and 
accompanying persistent cough. The performed 
laboratory examinations showed a significan-
tly lowered number of T CD4 lymphocytes — 
26 cells/μL, HIV viral load was 550 copies/mL. Mi-
crobiological examinations showed the presence 
of acid-fast bacilli in direct smears from sputum, 
additionally, bacilli culture from urine and spu-
tum were obtained. After about two months of 
hospitalization and therapy, the patient’s con-
dition had been gradually deteriorating, psychotic 
symptoms intensified and delusional symptoms 
appeared. MRI showed changes that could corre-
spond to encephalitis connected with HIV infec-
tion. Despite the applied intensive symptomatic 
and antituberculous treatment, the patient died. 
Postmortem examination showed disseminated 
mycobacteriosis with affected lymph nodes of the 
abdominal cavity (Fig. 2), spleen (Fig. 3), lungs, li-
Figure 2. Spleen mycobacteriosis (autopsy specimen). The picture 
shows multiple nodules crumbling whitish cream-colour (picture taken 
by the author)
Rycina 2. Mykobakterioza śledziony (materiał sekcyjny). Na zdjęciu 
widoczne mnogie rozpadające się guzki barwy białawo kremowej 
(zdjęcie wykonane przez autora)
Figure 3. Intra-abdominal lymph nodes mycobacteriosis (autopsy 
specimen). The picture shows significantly enlarged intra-abdominal 
lymph nodes packages (picture taken by the author)
Rycina 3. Mykobakterioza węzłów chłonnych wewnątrzbrzusznych (ma-
teriał sekcyjny). Na zdjęciu widoczne znacznie powiększone pakiety we-
wnątrzbrzusznych węzłów chłonnych (zdjęcie wykonane przez autora)
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ver and kidneys, with no affected central nervous 
system. The result of microbiological examination 
of the patient’s sputum, obtained after his death, 
showed the presence of MOTT with no identified 
species, resistant to rifampicin, isoniazid, etham-
butol and sensitive to streptomycin. 
The fatal course of the disease in the de-
scribed patients had many explanations. The 
main reasons were probably diagnosis of HIV 
and mycobacteriosis at the very late stage of HIV 
disease, and the ineffectiveness of the applied 
antituberculous treatment. Due to the observed 
significant deterioration of the patients’ condition 
after antiretroviral treatment, it may be presumed 
that the indirect cause of death was an accompa-
nying immune reconstitution syndrome. There 
were also observed adverse events during the 
applied therapy.
According to experts’ recommendations, 
HIV-infected patients with no symptoms of the 
disease and with the number of lymphocytes 
T CD4 < 50 cells/μL, should receive primary pre-
vention against MAC in the form of azithromycin, 
clarithromycin or rifabutin, until the function of 
the immune system is improved. It is extremely 
important to exclude mycobacteriosis and TB 
prior to onset of prevention [11, 24].
In Poland, next to mycotic infections (mainly 
Candida spp.), TB is the most frequent oppor-
tunistic disease that accompanies HIV/AIDS. 
It was also found that disseminated forms of TB 
are more frequently observed in HIV-infected 
patients than in the general population [25, 26]. 
In the present study, patients with disseminated 
TB accounted for a significant proportion of all 
study subjects (36.6%).
A positive phenomenon, observed among 
the population not infected with HIV, is a slow 
decline in incidence and mortality rates (and 
total number of deaths) due to TB, and mainta-
ining such a tendency in longstanding progno-
ses. Meanwhile, the TB incidence rate among 
HIV-infected patients has stayed at the same level 
with a minimal downward tendency, whereas 
according to longstanding observations, the total 
number of deaths due to HIV and TB coinfection 
is decreasing [2, 3].
It should be emphasized that each patient 
with diagnosed TB or mycobacteriosis should 
undergo testing directed at HIV infection, and 
HIV-infected patients should be diagnosed for 
the presence of TB or mycobacteriosis [11, 27]. 
According to a WHO report, in Poland in 2011 
maximally 15% of patients with diagnosed TB 
underwent testing directed at HIV infection. 
Positive examples of activity directed at HIV 
recognition in TB patients can be seen in Russia, 
the USA and many African countries, where HIV 
serological status is investigated in 75% of TB pa-
tients. Globally, in 2011, among TB patients who 
underwent testing directed at HIV infection, the 
proportion of positive results amounted to 23%. 
The proportion of positive results was different 
for individual regions of the world and it fluctu-
ated from 2.1% in Eastern Asia, through 3.5% in 
Central Asia and Western Europe, 6.8% in Eastern 
Europe to 46% in Sub-Saharan Africa [2].
Conclusions
In the studied population of HIV/AIDS pa-
tients, TB was diagnosed in 41 patients (10.5%) 
and mycobacteriosis in 4 patients (1.03%). 
In 42% of patients with coinfection, HIV and TB 
or mycobacteriosis were diagnosed simultaneo-
usly. A deep deficit in cellular immunity (CD4 < 
50 cells/μL) was more frequently observed in this 
group of patients, and HIV RNA viral load was 
significantly higher than in the remaining groups.
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